Clinical trial
Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)
NCT00258778 · Protalix, Industry · Completed
Key facts
| NCT number | NCT00258778 |
|---|---|
| Title | Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) |
| Official title | A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers |
| Lead sponsor | Protalix, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gaucher Disease |
| Intervention type | Drug |
| Interventions | Human Glucocerebrosidase (prGCD) |
| Enrollment | 6 |
| Start date | Nov 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Nov 28, 2005 |
| Last update posted | Dec 5, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: